SETD2 and neoplasm: This mechanism finds a parallel in the work of Xue Jing’s team, who demonstrated in pancreatic cancer that epigenetic dysregulation (e.g., SETD2 deficiency) can interact with metabolic reprogramming and potentially impair DDR-related pathways, thereby accelerating tumor progression (16).